Logo
Phone Icon
1-855-4-MEDINFO (855-463-3463)

1-855-4-MEDINFO (855-463-3463)

[email protected]
Back

INCB161734

INCB161734 is an investigational, oral, selective inhibitor of G12D-mutated KRAS.1

Recruiting & Ongoing Clinical Studies

Condition
Study Title
Phase
Resources & Links
Solid tumors
An Open-Label Study of INCB161734 Monotherapy or in Combination With Retifanlimab-dlwr, Cetuximab, GEMNabP, or mFOLFIRINOX in Patients With Advanced or Metastatic Solid Tumors With KRASG12D Mutation
1
NCT06179160 View Resource

G12D-Mutated Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)

G12D-Mutated Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)

KRAS is a membrane-bound GTPase that relays signals from receptor tyrosine kinases into downstream cascades that promote survival and proliferation.2,3

KRAS is one of the most frequently altered driver oncogenes in solid tumors.4,5

G12D is the most common KRAS mutant isoform (≈29% of oncogenic mutations in KRAS), with a high incidence in pancreatic and colorectal cancers and NSCLC.4

References: 1. Data on file. Incyte Corporation. 2. Erlanson DA, Webster KR. Curr Opin Chem Biol. 2021;62:101-108. 3. Simanshu DK, et al. Cell. 2017;170:17-33. 4. Lee JK, et al. NPJ Precis Oncol. 2022;6:91. 5. Zehir A, et al. Nat Med. 2017;23:703-713.

Top